Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C:: harmful impact of nevirapine

被引:0
|
作者
Macías, J
Castellano, V
Merchante, N
Palacios, RB
Mira, JA
Sáez, C
Palacios, RB
Mira, JA
Sáez, C
García-García, JA
Lozano, F
Gómez-Mateos, JM
Pineda, JA
机构
[1] Hosp Univ Valme, Unidad Enfermedades Infecciosas, Seville 41014, Spain
[2] Hosp Univ Valme, Med Interna Serv, Seville 41014, Spain
[3] Hosp Univ Valme, Serv Anat Patol, Seville 41014, Spain
[4] Hosp Univ Virgen Rocio, Serv Anat Patol, Seville, Spain
关键词
HCV coinfection; liver fibrosis; protease inhibitors; nevirapine;
D O I
10.1097/01.aids.0000111417.91384.fd
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The hepatotoxicity of highly active antiretroviral therapy (HAART) could enhance liver fibrosis in HIV/Hepatitis C virus (HCV)-coinfected patients. Moreover, HAART-related immune restoration could lessen HCV-associated liver damage. The data on the effect of protease inhibitors (PI) on liver fibrosis are scant and contradictory. No information is available on the relationship between non-nucleoside analogue therapy and liver fibrosis in co-infected patients. Objective: To investigate the associations between the use of different antiretroviral drugs and the liver fibrosis in patients with HIV and HCV infections. Design: Cross-sectional study. Methods: All HIV/HCV co-infected patients with an available liver biopsy and known or estimated duration of HCV infection seen at a Infectious Diseases Unit were included in the study. The fibrosis stage and the fibrosis progression rate were evaluated. Results: The inclusion criteria were fulfilled by 152 patients. Age at HCV infection < 20 years [adjusted odds ratio (AOR), 0.39; 95% confidence interval (Cl), 0.190.82], PI-based HAART (AOR, 0.39; 95% Cl, 0.19-0.78) and nevirapine-based HAART (AOR, 2.56; 95% Cl, 1.02-6.58) were associated with fibrosis stage greater than or equal to F3. The variables associated with fibrosis progression rate > 0.2 units/year were age at HCV infection < 20 years (AOR, 0.23; 95% Cl, 0.1-0.52), CD4 cell counts less than or equal to 250 x 10(6)/l at liver biopsy (AOR, 2.8; 95% Cl, 1.1-7.1), PI-based HAART (AOR, 0.39; 95% Cl, 0.2-0.8) and nevirapine-based HAART (AOR, 3.82; 95% Cl, 1.9-7.6). Conclusions: HAART regimens including nevirapine are associated with faster liver fibrosis progression in HIV-infected patients with chronic hepatitis C. In contrast, patients on PI as the backbone of potent antiretroviral therapy are more likely to show less liver fibrosis. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:767 / 774
页数:8
相关论文
共 50 条
  • [41] Enhanced Liver Fibrosis Panel as a Predictor of Liver Fibrosis in Chronic Hepatitis C Patients
    Fernandes, Flavia F.
    Ferraz, Maria L.
    Andrade, Luiz E.
    Dellavance, Alessandra
    Terra, Carlos
    Pereira, Gustavo
    Pereira, Joao L.
    Campos, Frederico
    Figueiredo, Fatima
    Perez, Renata M.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (03) : 235 - 241
  • [42] Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis
    Jain, Mamta K.
    Seremba, Emmanuel
    Bhore, Rafia
    Dao, Doan
    Joshi, Reeti
    Attar, Nahid
    Yuan, He-Jun
    Lee, William M.
    AIDS PATIENT CARE AND STDS, 2012, 26 (02) : 73 - 80
  • [43] Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy
    Vicente Fernandez-Montero, Jose
    Barreiro, Pablo
    Vispo, Eugenia
    Labarga, Pablo
    Sanchez-Parra, Clara
    Soriano, Vicente
    AIDS, 2013, 27 (07) : 1129 - 1134
  • [44] The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi
    Andreotti, Mauro
    Pirillo, Maria Franca
    Liotta, Giuseppe
    Jere, Haswell
    Maulidi, Martin
    Sagno, Jean-Baptiste
    Luhanga, Richard
    Amici, Roberta
    Mancini, Maria Grazia
    Gennaro, Elisabetta
    Marazzi, Maria Cristina
    Vella, Stefano
    Giuliano, Marina
    Palombi, Leonardo
    Mancinelli, Sandro
    BMC INFECTIOUS DISEASES, 2014, 14
  • [45] Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis C
    Ladero, Jose M.
    HEPATITIS MONTHLY, 2011, 11 (09) : 698 - 700
  • [46] Causative factors of liver fibrosis in HIV-infected patients. A single center study
    Androutsakos, Theodoros
    Schina, Maria
    Pouliakis, Abraham
    Kontos, Athanasios
    Sipsas, Nikolaos
    Hatzis, Gregorios
    BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [47] Causative factors of liver fibrosis in HIV-infected patients. A single center study
    Theodoros Androutsakos
    Maria Schina
    Abraham Pouliakis
    Athanasios Kontos
    Nikolaos Sipsas
    Gregorios Hatzis
    BMC Gastroenterology, 20
  • [48] High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs
    Allavena, C.
    Delpierre, C.
    Cuzin, L.
    Rey, D.
    Viget, N.
    Bernard, J.
    Guillot, P.
    Duvivier, C.
    Billaud, E.
    Raffi, F.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (09) : 2222 - 2230
  • [49] Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe
    Soriano, Vincent
    Mocroft, Amanda
    Peters, Lars
    Rockstroh, Juergen
    Antunes, Francisco
    Kirkby, Nikolai
    de Wit, Stephane
    Monforte, Antonella d'Arminio
    Flisiak, Robert
    Lundgren, Jens
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (03) : 548 - 555
  • [50] Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs
    Araujo, Susana
    Banon, Sara
    Machuca, Isabel
    Moreno, Ana
    Perez-Elias, Maria J.
    Casado, Jose L.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 171 (05) : 545 - 554